Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma

International Journal of Gynecological Cancer

Volumn 21, Issue 3, 2011, Pages 529-534

  Gupta, Divya ^a   Gunter, Marc J ^b   Yang, Kathleen ^c   Lee, Stephen ^b   Zuckerwise, Lisa ^b   Chen, Lee May ^c   Goldberg, Gary L ^b   Huang, Gloria S ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; CA125; UPSC; Uterine papillary serous carcinoma

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; UTERINE PAPILLARY SEROUS CARCINOMA; BLOOD; CYSTADENOCARCINOMA; METABOLISM; MIDDLE AGED; OMENTUM; PAPILLARY CARCINOMA; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE; UTERUS CANCER;

AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OMENTUM; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 80051609144     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821091b5     Document Type: Article

References (27)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society 2006.
2. Hendrickson M, Ross J, Eifel PJ, et al. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables. Gynecol Oncol. 1982;13:373-392. (Pubitemid 12090257)
3. Sherman ME, Bitterman P, Rosenshein MB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16: 600-610.
4. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797-806. (Pubitemid 30366266)
5. Gehrig PA, Groben PA, Fowler WC, et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol. 2001;97:153-157. (Pubitemid 32057174)
6. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463-469. (Pubitemid 38388137)
7. Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol. 2005;18:75-82. (Pubitemid 40128098)
8. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54:264-268. (Pubitemid 24301898)
9. Cirisano FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77:55-65. (Pubitemid 30217305)
10. Kato DT, Ferry JA, Goodman A, et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59:384-389.
11. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I-III) disease. Gynecol Oncol. 2001;81:279-286. (Pubitemid 32424175)
12. Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005;50:585-590. (Pubitemid 41193137)
13. Sood AK, Buller RE, Burger RA, et al. Values of preoperative CA-125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997;90:441-447. (Pubitemid 27357939)
14. Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501-1505.
15. Jhang H, Chuang L, Visintainer P, et al. CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol. 2003;188:1195-1197. (Pubitemid 36589100)
16. Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol. 2009;113:391-396.
17. Abramovich D, Markman M, Kennedy A, et al. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J Cancer Res Clin Oncol. 1999;125:697-698.
18. Tseng PC, Sprance HE, Carcangiu ML, et al. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol. 1989;74:384-387. (Pubitemid 19213928)
19. Price FV, Chambers SK, Carcangiu ML, et al. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer. 1998;82:1720-1725. (Pubitemid 28208923)
20. Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, et al. Utility of preoperative CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol. 2008;110:293-298.
21. Boruta DM 2nd, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153.
22. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw. 2009;7:55-556.
23. Huang GS, Chiu LG, Gebb JS, et al. Serum CA125 predicts extrauterine disease and survival in patients with uterine carcinosarcoma. Gynecol Oncol. 2007;107:513-517. (Pubitemid 350160866)
24. Fields AL, Einstein MH, Novetsky AP, et al. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2008;108:201-206. (Pubitemid 350299448)
25. Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol. 2009;112:558-562.
26. Fader AN, Drake RD, O'Malley DM, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119-2127.
27. Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98:353-359. (Pubitemid 41169144)